Catenin beta-1 (CTNNB1) (CTNNB1)

Catenin beta-1 (CTNNB1), commonly known as beta-catenin, is a multifunctional protein that serves as a critical structural component of cell-cell adherens junctions and a central transducer in the canonical Wnt signaling pathway [11, 12]. In the absence of Wnt ligands, cytoplasmic beta-catenin is continuously degraded by a destruction complex involving adenomatous polyposis coli (APC) and glycogen synthase kinase 3-beta (GSK3β) [2, 6]. Upon pathway activation, beta-catenin stabilizes, translocates to the nucleus, and acts as a transcriptional co-activator for T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors to drive the expression of genes involved in cell proliferation and stem cell maintenance [1, 19].\n\nDysregulation of this pathway, often through gain-of-function mutations in the CTNNB1 gene or loss-of-function mutations in APC, is a hallmark of numerous malignancies, particularly colorectal and hepatocellular carcinomas [8, 13]. Beyond oncology, beta-catenin is implicated in neurodevelopmental disorders (CTNNB1 syndrome), fibrosis, and bone density regulation [5, 7, 15]. Therapeutic strategies include small molecules that disrupt its interaction with nuclear co-activators like CBP or BCL9, as well as upstream inhibitors of Wnt secretion or receptor binding [10, 19, 20]. However, drug development faces significant challenges due to the protein's essential role in normal tissue homeostasis, particularly in the gut and bone, leading to potential dose-limiting toxicities [2, 3].

Other names

Beta-cateninCTNNBArmadillo homologCatenin (cadherin-associated protein) beta 1

Inhibition of beta-catenin/CBP or beta-catenin/BCL9 interactions, promotion of beta-catenin degradation via tankyrase inhibition, and inhibition of upstream Wnt ligand secretion or receptor binding [10, 18, 19, 20].